A German real-world study has found that people with severe COPD and type-2 inflammation experienced roughly 70 percent fewer exacerbations after starting dupilumab, according to Lungeninformationsdienst, the patient information service of the German Center for Lung Research (DZL). The analysis drew on treatment records from 99 patients across 14 German lung centres, with researchers following participants for a median of eleven months after the first dose. The work was published in Respiratory Research in 2026.
Why it matters
COPD is a chronic condition in which repeated acute worsenings, known as exacerbations, drive much of the long-term damage to the lungs and the loss of quality of life. Reducing those episodes is a central goal of treatment, and any therapy that achieves it outside the controlled conditions of a clinical trial is of practical interest to patients and clinicians alike. Dupilumab, a biologic that blocks immune signalling molecules that promote inflammation, has been approved in Germany since June 2024 for certain forms of COPD. It is intended for people whose disease is driven by type-2 inflammation and who continue to suffer frequent flare-ups despite their existing treatment.
The new study set out to test how the drug performs in ordinary medical practice rather than in the tightly managed setting of a randomised trial. According to Lungeninformationsdienst, the researchers also observed a decline in severe exacerbations requiring hospital admission, although the summary did not quantify that reduction.
Symptom burden eased alongside flare-ups
Beyond counting exacerbations, the team assessed how much COPD was interfering with patients' daily lives. They used the COPD Assessment Test, a questionnaire that covers criteria such as breathlessness, mucus production and cough. Sixty-five percent of participants reported a noticeable improvement in these symptoms after beginning treatment, Lungeninformationsdienst reports.
The findings align with earlier evidence. A phase-III trial had already shown that dupilumab could lower exacerbation rates and improve lung function in COPD patients with type-2 inflammation, and the real-world data now suggest a similar pattern holds when the drug is used in routine care.
A missing comparison group
The study carries a significant limitation. It included no control group of patients who did not receive dupilumab, so the researchers cannot say with certainty how much of the observed improvement is attributable to the drug itself. Other factors — changes in background therapy, seasonal variation or the natural course of the disease — could account for part of the effect. Lungeninformationsdienst notes that larger studies are needed to establish which groups of patients benefit most.
That caveat matters because biologics are costly and not suitable for everyone with COPD. Identifying the patients most likely to respond is an open question. Separate research highlighted by Lungeninformationsdienst suggests that the effectiveness of dupilumab varies considerably between individuals, and scientists are investigating blood markers, including interleukin-18 levels, as possible predictors of response.
The broader COPD research picture is also moving. Recent work has linked higher values on the TyG index to a greater likelihood of developing COPD and of suffering severe complications among those who already have it, based on a review of data from nearly 489,000 people. Other analyses have pointed to swallowing difficulties, known as dysphagia, as potentially more consequential for the course of the disease than previously recognised. And two large international trials of the antibody astegolimab produced conflicting results on whether it can reduce exacerbations.
For now, the German multicentre analysis offers a practical signal: in everyday respiratory care, patients with severe COPD and type-2 inflammation who received dupilumab had fewer flare-ups and reported easier breathing. What remains to be settled is how much of that belongs to the drug and who stands to gain most.
